Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
These Stocks Are Moving the Most Today: Coinbase, MicroStrategy, Sarepta, Nvidia, AMD, and More
05:26am, Monday, 11'th Aug 2025
Coinbase and MicroStrategy stocks rose as Bitcoin price surged. Shares of Sarepta, Nvidia and AMD were falling in early trading Monday.
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). S
SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)
07:36am, Saturday, 09'th Aug 2025
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
SAN DIEGO , Aug. 8, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June
NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
SRPT Deadline: SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
03:22pm, Friday, 08'th Aug 2025
NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
10:50am, Friday, 08'th Aug 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options If you purchased or acquired
SAN FRANCISCO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- On July 24, 2025, the European Medicines Agency (“EMA”) recommended the refusal of the marketing authorization for ELEVIDYS, Sarepta's medication i
August 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SRPT
08:45am, Friday, 08'th Aug 2025
NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS D
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023
Investors can contact the law firm at no cost to learn more about recovering their losses
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) - August 25, 2025 Deadline to Join – Contact The Gross Law Firm
04:32pm, Thursday, 07'th Aug 2025
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).
Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries
10:32am, Thursday, 07'th Aug 2025
SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.
